Gedea Biotech took third prize at the EU competition EIT Health

Gedea Biotech came in third place in yesterday’s European final of the EIT European Health Catapult in the Biotech category. Gedea was also the audience winner. This means that the company is one of Europe’s absolute best startup companies in health. Gedea Biotech is a member of SmiLe Incubator and is one of LU Holding’s portfolio companies.

Gedea Biotech won EUR 10,000 for third prize and received EUR 10,000 after being named the audience favorite, which means it received as much as the first prize winner, a total of EUR 20,000. After months with a number of semifinals, the final was held yesterday, December 4, at the EIT Health Summit in Lodz, Poland.

“A huge congratulations to Annette Säfholm, CEO of Gedea, who convincingly presented the company’s tremendous potential in today's final. This entire journey has of course provided Gedea with many important contacts, including top-ranked international investors, while showcasing the high standard of southern Sweden’s innovative companies and university research. It is also confirmation that SmiLe’s support in business development provides companies with a strong boost in their development,” says Ebba Fåhreaus, CEO at SmiLe Incubator.      

 

Gedea Biotech’s operations are based on research at Lund University by Olov Sterner, Sophie Manner and Ulf Ellervik at Kemicentrum, along with Helena Strevens, an obstetrician/gynecologist with the Department of Obstetrics and Gynecology at Skåne University Hospital. 

Gedea Biotech is a members of SmiLe Incubator, a business incubator in the life sciences that helps entrepreneurs to commercialize their ideas by offering business advisory services, laboratories and networks. The companiy is also in LU Holding’s business portfolio. www.smileincubator.life  www.innovation.lu.se

 

About Gedea Biotech: Gedea Biotech is developing a new treatment method for vaginal infections. Vaginal infections can be caused by both bacteria and fungi and Gedea’s treatment is expected to be highly efficacious for treating both conditions. The first clinical study is conducted using GDA001 in patients with vaginal fungal infections. 
Contact: Annette Säfholm, CEO, +46 (0)708-918681, www.gedeabiotech.com

About EIT Health: EIT Health – Together for healthy lives in EuropeEIT Health is a high-quality European network with more than 140 partners from industry, academia, and payers/providers of health care in Europe. Region Skåne is a Core Partner since 2018, which gives companies with a relation to the regional innovation system an opportunity to seek funding for international growth. Innovation Skåne is responsible for the program's coordination in the region. For more information, see eithealth.eu or contact bengt.stavenow@innovationskane.com 

---

---